Trials
TUSTIN, CA: Peer-Reviewed Data Show Peregrine Pharmaceuticals' PS-Targeting Antibody Bavituximab Exhibits Specific and Strong Binding to Ebola Virions and Ebola Virus-Infected Cells In Vitro; Data Supplement ...
FAIRFIELD, NJ: StayinFront Life Sciences CRM and Analytics Solution to Support a New Specialty Sales Force With Integrated Capabilities for Advanced Customer Targeting, Closed Loop Marketing (CLM), and Performance T ...
SAN DIEGO, CA: Ongoing Dialogue With FDA Aimed at Initiating Clinical Trial for IND # 15376
...
BOSTON, MA: Decreasing Image Interpretation Variability in Cancer Trials Can Result in Decreased Trial Sample Size, Thus Driving a Decrease in Trial Cost
...
PARSIPPANY, NJ: 27% Increase in Third Quarter 2013 Net Revenue to $174.3 Million; 26% Increase YTD September 2013 Net Revenue to $502.9 Million; Net Income in Third Quarter 2013 Totals $7.8 Million or $0.12 per Share ...
TUSTIN, CA: Bavituximab Pivotal Phase III Lung Cancer Trial Named "SUNRISE" on Track for Initiation by Calendar Year-End; Bavituximab Pre-Clinical Proof-Of Concept Studies Underway to Support Potential ...
TUSTIN, CA: Presentation Reviews Bavituximab's and Docetaxel's Compatible Immune-Stimulating Properties Further Supporting Initiation of Phase III Trial in Second-Line NSCLC by Year-End; Proof-of-Concep ...
PHOENIX, AZ: Reports Record Revenue of $18.8 Million and EPS of $0.26 per Diluted Share
...
BOSTON, MA: New Service Enables Combination Tumor Assessments Using Both RECIST and irRC
...
